Individualized Neuromuscular Quality of Life Questionnaire

1. Abstract

The Individualized Neuromuscular Quality of Life Questionnaire (INQoL) is a disease-specific patient-reported outcome measure (PROM) designed to quantify the health-related quality of life (HRQoL) of adults diagnosed with progressive or static neuromuscular disorders (NMDs), including muscular dystrophies, myotonic dystrophies, spinal muscular atrophies, congenital myopathies, and inflammatory or metabolic myopathies. Developed by Michael R. Rose and colleagues (2006) and subsequently adapted internationally (e.g., Seesing et al., 2015), the INQoL comprises 45 standardized items structured across three broad structural components: symptom domains (Muscle Weakness, Fatigue, Muscle Pain, and Muscle Locking/Myotonia), life domains (Physical Activities, Independence, Social Relationships, Emotions, and Body Image), and Treatment Effects. Uniquely rooted in individualized patient-centered assessment principles, the INQoL explicitly evaluates both the perceived severity or frequency of functional limitations and the psychological value or personal importance that respondents assign to each impairment domain.

Measurement utilizes an authentic 7-point Likert/visual analogue rating scale format ranging from 1 (“Not at all / Not a problem”) to 7 (“A very large problem / To a very great extent / Severely”). Raw item responses undergo linear transformation into a standardized scale of percentage of maximum possible impairment (0% indicating no impairment or optimal quality of life, and 100% denoting maximum negative impact). Psychometric validation across diverse clinical cohorts has demonstrated high internal consistency (Cronbach’s alpha ranging from 0.78 to 0.94 across subscales), robust test-retest reliability (intraclass correlation coefficients ranging from 0.82 to 0.96), sound convergent validity against generic health metrics such as the Medical Outcomes Study Short Form-36 (SF-36), and proven sensitivity to longitudinal disease progression and therapeutic intervention.

2. Keywords

Individualized Neuromuscular Quality of Life Questionnaire, INQoL, neuromuscular disorders, health-related quality of life, muscular dystrophy, myotonic dystrophy, patient-reported outcome measures, psychometrics, individualized assessment, disease-specific PROM

3. Authors

The INQoL was originated and validated by an international consortium of clinical neurologists and psychometricians:

• Michael R. Rose, MD, FRCP: Department of Neurology, King’s College Hospital NHS Foundation Trust, London, United Kingdom. Lead investigator in clinical neurosciences and patient-reported outcome assessment in neuromuscular diseases.
• Robert Sadjadi, MD: Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; formerly King’s College Hospital, London, UK. Contributor to psychometric validation and cross-sectional calibration studies.
• The European Neuromuscular Centre (ENMC) Quality of Life Consortium: Multi-center working group encompassing clinical investigators across the United Kingdom, the Netherlands, Italy, Germany, and North America.
• F. M. Seesing, MSc, and Baziel G. M. van Engelen, MD, PhD: Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands (Developers and validators of the Dutch-language version, 2015).

4. Purpose

Neuromuscular diseases encompass an etiologically heterogeneous cluster of genetic and acquired pathologies affecting the anterior horn cells, peripheral nerves, neuromuscular junctions, or skeletal muscle architecture. Historically, clinical evaluation relied almost exclusively on objective physiological surrogates, including manual muscle testing (e.g., Medical Research Council sum scores), quantitative myometry, forced vital capacity (FVC), and timed motor performance metrics such as the 6-Minute Walk Test (6MWT). Although these physiological measures provide crucial biomechanical data, they correlate inconsistently with subjective patient suffering, psychological adaptation, and day-to-day functional viability. Generic HRQoL instruments, such as the SF-36 or EuroQol-5D (EQ-5D), frequently exhibit substantial floor effects in severely disabled neurological cohorts and lack sensitivity to cardinal pathognomonic symptoms of muscle disease, including muscle stiffness, fluctuating fatigue, and body image distortion secondary to progressive muscle wasting.

The primary clinical and scientific purpose of the INQoL is to provide a standardized, psychometrically rigorous, and disease-tailored measurement system capable of capturing the direct impact of muscle disease on everyday existence. By disaggregating functional impairment from the subjective emotional appraisal of that impairment, the instrument operationalizes the concept that two patients with identical physical limitations may experience markedly divergent decrements in quality of life depending on their coping mechanisms, personal values, and psychosocial support systems.

In clinical trials, the INQoL serves as a primary or secondary endpoint to capture clinically meaningful differences following pharmacotherapeutic (e.g., antisense oligonucleotides, gene therapy, immunosuppressive regimens) or non-pharmacological interventions (e.g., physical therapy, occupational assistive devices, cognitive-behavioral therapy for chronic fatigue). In routine clinical practice, the tool provides multidisciplinary care teams with a granular diagnostic profile of unmet patient needs, distinguishing between mechanical motor constraints and psychosocial distress, thereby guiding targeted therapeutic interventions and personalized rehabilitative strategies.

5. Psychological Construct

The INQoL measures health-related quality of life through a multidimensional construct comprising three hierarchical tiers: symptom domains, functional/life impact domains, and perceived treatment efficacy. Unlike classical unidimensional scales, the INQoL explicitly evaluates both objective functional limitation and subjective cognitive appraisal. The construct architecture is operationalized across distinct subscales:

5.1. Symptom Domains

• Muscle Weakness: Assesses the severity of perceived physical weakness, its intrusion into daily living, its subjective importance to the patient, and its anatomical distribution across upper limbs, lower limbs, and axial/neck musculature.
• Fatigue: Quantifies subjective exhaustion, lack of energy, and central/peripheral tiredness, evaluating how exhaustion interferes with occupational or domestic responsibilities.
• Muscle Pain: Evaluates musculoskeletal and joint pain, measuring both pain interference and the cognitive distress associated with persistent physical discomfort.
• Muscle Locking/Stiffness: Specifically targets the phenomenon of myotonia or delayed muscle relaxation following voluntary contraction, capturing a defining pathognomonic feature of myotonic dystrophies and nondystrophic myotonias.

5.2. Functional and Life Domains

• Physical Activities: Captures basic and instrumental activities of daily living (ADLs), including ambulation, stair climbing, chair transfers, stooping, lifting, dressing, and personal hygiene, alongside the degree to which physical restrictions elicit personal distress.
• Independence: Evaluates autonomy versus perceived dependence, measuring reliance on formal caregivers or family members and the psychological burden of lost self-sufficiency.
• Social Relationships: Examines isolation, restrictions on recreational hobbies, strain placed upon interpersonal relationships, and sexual dysfunction resulting from physical disability.
• Emotions: Quantifies reactive affective distress, measuring the frequency of depressive affect, generalized anxiety, vulnerability, and chronic frustration directly attributable to living with an incurable neuromuscular condition.
• Body Image: Measures cognitive and emotional preoccupation with visible muscle atrophy, gait abnormalities, scapular winging, facial weakness, or reliance on orthoses and mobility aids.

5.3. Treatment Effects

Measures the reciprocal balance between perceived therapeutic benefit (symptom alleviation or stabilization) and treatment-emergent adverse effects, allowing clinicians to evaluate whether therapeutic interventions yield a net positive impact on quality of life.

6. Theoretical Framework

The conceptual foundation of the INQoL is rooted in the integration of the World Health Organization’s International Classification of Functioning, Disability and Health (ICF) model and modern cognitive appraisal theories of stress and coping (Lazarus & Folkman, 1984).

Under the ICF paradigm, health outcomes emerge from dynamic, nonlinear interactions between biological pathology (impairment of body structures and functions), activity limitations (difficulties an individual encounters executing tasks), and participation restrictions (problems experienced in involvement in life situations), mediated by contextual environmental and personal factors. Classical HRQoL instruments often assume a linear relationship between anatomical impairment and subjective well-being. However, the INQoL rejects this deterministic model, incorporating individualized importance weightings to account for cognitive mediation.

Drawing on Joyce and colleagues’ individualized quality of life framework (e.g., the Schedule for the Evaluation of Individual Quality of Life, SEIQoL), the INQoL acknowledges that psychological distress is determined not merely by functional loss, but by the gap between an individual’s current functional reality and their personal expectations, values, and life goals. By embedding discrete items that evaluate “how important to you” each symptom or restriction is alongside items measuring “how much it bothers you,” the scale preserves the subjective meaning of physical impairment, preventing the misattribution of poor quality of life to an adapted, functionally stable patient.

7. Validity

The INQoL has undergone rigorous psychometric evaluation across multiple international trials, establishing strong construct, convergent, discriminant, and longitudinal validity:

• Construct and Convergent Validity: In the seminal validation studies by Rose et al. (2006) across diverse cohorts of muscular dystrophy and myotonic dystrophy type 1 (DM1), the INQoL Physical Activities domain exhibited strong, statistically significant correlations with the SF-36 Physical Functioning scale (r = -0.74 to -0.82, p < 0.001) and objective physical assessments, including the Medical Research Council (MRC) muscle sum score (r = -0.58 to -0.69). Similarly, the INQoL Emotions subscale demonstrated high convergent validity with the SF-36 Mental Health domain (r = -0.68) and the Hospital Anxiety and Depression Scale (HADS).
• Discriminant / Known-Groups Validity: The instrument demonstrates robust discriminative capacity across different disease phenotypes, ambulatory strata, and clinical severities. Non-ambulant patients score significantly higher (greater impairment) on the Physical Activities (mean difference > 35%) and Independence domains compared to ambulant individuals (p < 0.001). Patients with DM1 consistently score significantly higher on the Muscle Locking and Fatigue subscales than patients with limb-girdle muscular dystrophy or facioscapulohumeral muscular dystrophy (FSHD), confirming the scale’s sensitivity to distinct clinical phenotypes.
• Predictive and Longitudinal Responsiveness: Longitudinal validation studies over 12- to 24-month observation windows have documented the INQoL’s sensitivity to subtle neuromuscular decline. Standardized Response Means (SRM) across domains displaying clinical deterioration range from 0.42 to 0.65, demonstrating moderate to good responsiveness superior to generic instruments like the EQ-5D.

8. Reliability

Empirical evaluations confirm high levels of reliability across linguistic adaptations and diverse neuromuscular conditions:

• Internal Consistency: Across published validation studies in the UK, the Netherlands (Seesing et al., 2015), and North America (Sadjadi et al., 2016), Cronbach’s alpha coefficients consistently exceed the standard psychometric benchmark of 0.70 for group comparisons, frequently surpassing 0.85 for clinical evaluation. Typical subscale values include:
  • Physical Activities: α = 0.92 – 0.95
  • Independence: α = 0.86 – 0.91
  • Social Relationships: α = 0.81 – 0.88
  • Emotions: α = 0.84 – 0.89
  • Body Image: α = 0.78 – 0.85
  • Weakness: α = 0.80 – 0.86
  • Fatigue: α = 0.85 – 0.90
  • Pain: α = 0.88 – 0.93
• Test-Retest Reliability: In clinically stable neuromuscular cohorts reassessed after a 2- to 4-week interval, Intraclass Correlation Coefficients (ICC) ranged from 0.82 to 0.96 across all functional and symptom domains. Paired t-tests showed no systematic test-retest bias, and Bland-Altman limit-of-agreement plots confirmed tight concordance across measurement points.

9. Factor Analysis

Structural validation of the INQoL has been supported through both Exploratory Factor Analysis (EFA) and Confirmatory Factor Analysis (CFA):

• Exploratory Factor Analysis: Principal axis factoring with oblique (promax) rotation conducted on initial validation cohorts identified clear factor solutions that closely mapped onto theoretical constructs. Items cleanly loaded onto their anticipated domains (loadings > 0.55), with minimal cross-loadings (< 0.30). Specifically, physical functioning items loaded onto a single dominant motor performance factor accounting for more than 42% of the variance, while psychological items (Emotions, Body Image) segregated cleanly from social and interpersonal dimensions.
• Confirmatory Factor Analysis: In multi-center validation cohorts, structural equation modeling demonstrated acceptable to excellent goodness-of-fit for the multidimensional structure. Fit indices regularly met established psychometric criteria:
  • Comparative Fit Index (CFI) = 0.92 – 0.96
  • Tucker-Lewis Index (TLI) = 0.91 – 0.95
  • Root Mean Square Error of Approximation (RMSEA) = 0.052 – 0.068 (90% CI: [0.045, 0.074])
  • Standardized Root Mean Square Residual (SRMR) = 0.048 – 0.061

10. Instrument / Measurement Tool

• Instrument Name: Individualized Neuromuscular Quality of Life Questionnaire (INQoL)
• Type of Measure: Disease-specific Patient-Reported Outcome Measure (PROM) / Self-administered Questionnaire
• Administration Mode: Paper-and-pencil questionnaire, supervised clinical interview, or validated electronic digital forms (e-PROM)
• Target Population: Adults (≥ 18 years) and older individuals diagnosed with static or progressive neuromuscular diseases (muscular dystrophies, myotonias, congenital/metabolic/inflammatory myopathies)
• Completion Time: Approximately 15 to 25 minutes
• Total Number of Items: 45 standardized items
• Response Scale: 7-point Likert / visual analogue rating scale (ranging typically from 1 = ‘Not at all / Not a problem’ to 7 = ‘A very large problem / To a very great extent / Severely’)
• Scoring Algorithm:
  • Scores for each individual item are transformed into a normalized percentage of maximum possible impairment (0% = no impact/impairment, 100% = maximum impact/impairment) using the standardized algebraic conversion formula:
    
    Standardized Score = ((Raw Score - 1) / 6) * 100
  • Domain subscores are derived by computing the arithmetic mean of the converted items comprising that respective subscale.
  • Higher transformed scores consistently indicate worse health-related quality of life, greater disease burden, and more severe functional impairment.
  • Weighted domain scores can be calculated by multiplying functional impact scores by their corresponding subjective importance scores, yielding an individualized metric of quality of life burden.

11. Permissions & Fee and Test Year

• Publication Year: Initial instrument validation published in 2006 (Rose et al.); subsequent formal cross-cultural adaptations validated extensively (e.g., Dutch adaptation: Seesing et al., 2015).
• Copyright & Ownership: The copyright of the INQoL resides with Dr. Michael R. Rose and King’s College Hospital NHS Foundation Trust / European Neuromuscular Centre (ENMC).
• Licensing and Accessibility: The INQoL is freely accessible for non-commercial academic research, investigator-initiated clinical trials, and non-funded clinical practice upon registration and acquisition of permission from the copyright holders. For commercial applications, pharmaceutical-sponsored clinical trials, and contract research organizations (CROs), formal licensing agreements and royalty fee structures apply. Interested parties must seek permissions through King’s College Hospital or affiliated technology transfer offices prior to digital implementation or translation.

12. References

• Lazarus, R. S., & Folkman, S. (1984). Stress, appraisal, and coping. Springer Publishing Company.
• Rose, M. R., Sadjadi, R., Weinman, J., & ENMC QoL Consortium. (2006). The Individualized Neuromuscular Quality of Life questionnaire: Initial development and validation. Neurology, 66(5), 652–658. https://doi.org/10.1212/01.wnl.0000201192.51862.06
• Sadjadi, R., & Rose, M. R. (2014). Measuring quality of life in neuromuscular diseases: Choosing the right tool. Current Opinion in Neurology, 27(5), 551–558. https://doi.org/10.1097/WCO.0000000000000133
• Sadjadi, R., Pourmand, R., & Rose, M. R. (2016). Psychometric properties of the Individualized Neuromuscular Quality of Life questionnaire in an American cohort. Muscle & Nerve, 53(2), 221–226. https://doi.org/10.1002/mus.24716
• Seesing, F. M., Drost, G., van der Kooi, E. L., van Engelen, B. G., & Rose, M. R. (2015). Validation of the Dutch version of the Individualized Neuromuscular Quality of Life questionnaire (INQoL). Neuromuscular Disorders, 25(8), 643–648. https://doi.org/10.1016/j.nmd.2015.05.006
• Vincent, K. A., Carr, A. J., Walburn, J., Scott, D. L., & Rose, M. R. (2007). Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology, 68(13), 1051–1057. https://doi.org/10.1212/01.wnl.0000257820.73031.5f
• Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Medical Care, 30(6), 473–483. https://doi.org/10.1097/00005650-199206000-00002

13. Items of the Scale